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ABSTRACT
PREDICTIVE MODELING OF CLINICAL OUTCOMES FOR HOSPITALIZED
COVID-19 PATIENTS UTILIZING CYTOF AND CLINICAL DATA
Onajia Stubblefield
July 22, 2021
In December 2019, an outbreak of a novel coronavirus initiated a global pandemic.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that causes the
disease coronavirus disease 2019 (COVID-19). Symptoms of infection with COVID-19
vary widely between individuals. While some infected individuals are asymptomatic,
others need more extensive care and require hospitalization. Indeed, the COVID-19
pandemic was characterized by a shortage of hospital beds which presented additional
complications in providing adequate care for patients. In this study, we used a
combination of T cell population data collected from mass cytometry analysis and
clinical markers to form a predictive model of clinical outcomes for hospitalized COVID19 patients. This paper details the steps and analysis towards the design of the final model
including data acquirement and preprocessing, missing data handling via multiple
imputation, and repeated imputations inferences.
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CHAPTER I
INTRODUCTION

1.1

Introduction
In December 2019, a new virus emerged that quickly spread around the globe in

early 2020: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARSCoV-2 triggers a clinical disease named coronavirus disease 2019 or, succinctly, COVID19 (Subbarao and Mahanty, 2020). COVID-19 causes a respiratory tract infection that
can affect the upper respiratory tract including sinuses, noses, and throat and/or lower
respiratory tract including the windpipe and lungs. Symptoms of the virus include fever,
coughing, fatigue, and muscle and body aches (Adil et al., 2013). Interestingly,
symptomatic expressions of the virus can vary significantly between individuals. Severity
of symptoms can range from asymptomatic yet still potentially contagious to mildly or
moderately symptomatic to severe. Severe cases, approximately 20% of all cases, require
mechanical ventilation and could result in death (Adil et al., 2013).
SARS-CoV-2 viral infection leads to humoral and cellular responses from the
immune system (Shah et al., 2020). B cells are the primary drivers of the humoral
response in the human system, developing antibodies that bind to target antigens on
viruses. T cells are the primary drivers of cellular response, also known as cell-mediated
immunity. In cell-mediated immunity, whose chief purpose is elimination of virally
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infected cells, naïve T cells that encounter viral antigen proliferate and differentiate to
produce memory T cells which rapidly initiate a secondary response upon subsequent
infections (Shah et al., 2020). T cell counts have been shown to reflect the severity of
COVID-19 (Zheng et al., 2020; Diao et al., 2020; Liu et al., 2020). Studies associating T
cells with COVID-19 primarily look at the cell counts. Furthermore, the scope of these
studies is commonly limited to the CD4+ and CD8+ populations without examination of
their subtypes: memory T cells and naïve T cells.
In addition to T cell populations, previous research has also used laboratory
clinical markers to monitor the status of hospitalized COVID-19 positive patients.
Generally, severe patients exhibit increased levels of D-Dimers, C-reactive Protein
(CRP), ferritin, and lactate dehydrogenase (LDH) over the course of their hospitalization
(Kermali et al., 2020). Furthermore, certain comorbidities are associated with increased
COVID-19 mortality including lung cancer (Passaro et al., 2021), chronic kidney disease
(Sanyalu et al., 2020), and human immunodeficiency virus (HIV) (Ssentogo et al., 2021).
In this study, we collected information on T cell populations from hospitalized
COVID-19 positive patients as well as a variety of laboratory values and comorbidity
data from their electronic health records. Our goal was to utilize this data and create links
to the clinical outcomes (i.e. discharged from hospital, ventilation, transferal to ICU,
death, etc.) of these individuals. We hypothesize that measurements performed only at
hospital admission narrowly characterize the clinical impact and course of COVID-19.
Clinical status, initially measured laboratory values, and immune cell populations
fluctuate throughout the duration of infection. Thus, longitudinal monitoring and analysis
is essential for a holistic view of the immune system reactions and other physiological
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responses to SARS-CoV-2 infection. In this paper, we present our modeling of
longitudinal COVID-19 clinical outcomes constructed using naïve and memory T-cell
population proportions, laboratory values, and comorbidities. This study will hopefully
help clinicians determine the most important markers and factors in monitoring and
predicting the trajectory of SARS-CoV-2 infection. Ultimately, this could help evaluate
the most efficient allocation of resources such as ICU beds and mechanical ventilators.
The structure of the paper will be as follows: in this Introduction, we will provide
a brief overview of longitudinal studies and longitudinal data, discussing balanced versus
unbalanced data and the advantages and disadvantages of longitudinal studies. We will
also provide the definitions of missing data and multiple imputation which we implement
as a resolution to missing data. These introductions will lay the foundation for our study.
In the Methods and Materials section, we provide the inclusion and exclusion
criteria of the study’s subjects, describe how we transformed the clinical outcomes to
ordinal data, and detail the attainment of the lab values or clinical markers. In addition,
we describe the processes that occur in a mass cytometer which ultimately produce Flow
Cytometry Standard (FCS) files to analyze. We then share our gating strategy to collect
information on the T cell populations from these FCS files. Lastly, we summarize the
cytometry by time of flight (CyTOF) data and statistical analyses methods and packages
used.
The CyTOF Data Analysis section of this paper will discuss additional, insightful
visualization options of the CyTOF data such as t-SNE, principal component analysis
(PCA), and heatmap plots. The visualizations were used cross-check the values obtained
from the gating performed in the Methods and Materials section.
3

The Statistical Analysis body of this paper will cover the statistical theory and
methods that form the bulk of our study. Among these include the preprocessing of
variables using Pearson correlation, MICE (Multivariate Imputation via Chained
Equations) imputation to impute missing clinical marker values, repeated measurements
inferences, and creation of mixed effect models for longitudinal data.
The fifth section in the body of the paper will lay out the results of the study,
including descriptions of the demographic data overall. We also included tables that
summarize the data (Table 1), give the significantly correlated variables (Table 2), and
provide the final output of the pooled cumulative link mixed model for ordinal outcomes
(Table 3).
The fifth section will provide more in-depth discussion of the results and potential
opportunities for future research.
The Appendix of this paper provides additional tables, models, and a glossary
related to the study that were deemed noncritical for inclusion in the body of the paper,
but useful nevertheless for the reader who may want even more details regarding the
analysis.
1.2

Introduction to longitudinal studies
Longitudinal studies are a dynamic approach to scientific investigation. In a

longitudinal study, variables from a defined group of individuals are followed over an
extended period of time (Coggon et al., 2009, Chapter 7). The purpose of a longitudinal
study is to characterize changes in the response of interest over time in relation to the
selected covariates. There are variety of types of longitudinal studies including cohort
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studies, panel studies, and record linkage studies - all of which can be prospective or
retrospective (Caruana et al., 2015).
There are two types of design in longitudinal data analysis: balanced and
unbalanced. In balanced design, repeated measurements are taken at the same intervals
(Liu, 2016). In unbalanced design, the set of time points for the subjects are different
(Liu, 2016). In addition to our data being unbalanced with different time intervals
between samples, some patients had more observations than others.
Figure 1. Balanced and unbalanced longitudinal data. Panel A. Visualization of balanced
longitudinal data; Panel B. Visualization of unbalanced longitudinal data.

Longitudinal studies offer numerous benefits. Among these include the ability to
identify and relate events to specific exposures, establishing a sequence of events after
exposure, eliminating recall bias in subjects, and monitoring change in particular
individuals over the course of time (Caruana et al., 2015). Simultaneously, longitudinal
5

studies come with obstacles as well. The longer a study is, the more likely it is for
individuals to follow-up at subsequent times (Caruana et al., 2015). These types of
studies are, in general, more costly in terms of financial demands and time requirements
(Caruana et al., 2015). To counter this, investigators typically opt for a smaller group of
subjects.
1.3

Longitudinal data analysis
A variety of statistical methods have been developed that can accommodate for

different classes of response variables in longitudinal data. If the response variable is
continuous, linear mixed effect models are commonly used whereas if the response
variable is discrete, generalized linear mixed effect models are utilized. Discrete response
variables include nominal responsible variables, which contain no quantitative value, and
ordinal response variables, in which order matters but the differences between levels is
unknown. Treating the clinical outcome as an ordinal response variable, the model of
interest for this study was the cumulative link mixed model. We will delve more into this
model in the Analysis section.
1.4

Missing data & multiple imputation
In statistics, missing data occur when any observation of interest has no stored

data value for any variable. Though a longitudinal analysis can have a balanced design, if
missing data is present, the data is unbalanced. Moreover, missing data is common in
unbalanced longitudinal studies as well which, if neglected, can reduce the statistical
power of study, induce bias in the estimation of parameters of interest, and reduce the
representativeness of the samples (Kang 2013). If missing data are mishandled, incorrect
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inferences about the parameters can be drawn. To prevent these inappropriate inferences,
there are different strategies and techniques for handling missing data. In this study, we
investigate and utilize a multiple imputation strategy in which plausible data sets are
imputed to replace the missing values. The imputed values in these data sets contain the
natural variability and estimation uncertainty of the correct values which produces a valid
statistical inference.
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CHAPTER II
METHODS AND MATERIALS

2.1

Study participants
The Institutional Review Board at University of Louisville approved the present

study and written informed consent was obtained from either subjects or their legal
authorized representatives (IRB No. 20. 0321). Inclusion criteria were hospitalized adults,
age 18 or older, at the University of Louisville Hospital with positive COVID-19 test
results and provided consent to this study. Exclusion criteria included less than 18 years
of age and/or refusal to participate. COVID-19 patients enrolled in this study were
diagnosed with a 2019-CoV detection kit at the University of Louisville Hospital
Laboratory using real-time reverse transcriptase–polymerase chain from nasal pharyngeal
swab samples obtained from patients. All COVID-19 patients were followed by the
research team daily and the clinical team was blinded to findings of the research analysis
to avoid potential bias.
2.2

Clinical data & markers
The ordinal ranking of clinical outcomes from 1 to 5 is based on the clinical

observation. A clinical outcome assigned the value of 1 meant the patient was discharged
the same day. A value of 2 meant the patient was sent to the floor or extubated. If the
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patient was sent to the ICU that day, the clinical observation was given the value 3. If the
patient was intubated, the clinical observation was assigned a value 4. Death on the day
of draw was 5. This clinical ordinal outcome is our primary outcome of this study.
The demographic characteristics (age, sex, height, weight, Body Mass Index
(BMI), clinical data (symptoms, comorbidities, laboratory findings, treatments,
complications and outcomes) and results of cardiac examinations including biomarkers,
ECG and echocardiography were collected prospectively. All data were independently
reviewed and entered into a computer database. These data were then extracted to form a
final data set along with the CyTOF data. The laboratory values can be found in the
Discussion section in Table 1. For hospital laboratory CBC (complete blood count) tests,
normal values are the following: white blood cell (4.1-10.8 x103 /µL); hemoglobin (13.717.5gram/dL); and platelet (140-370 x103 /µL). For hospital laboratory inflammatory and
coagulation markers, normal values are the following: D-dimer (0.19-0.74 µgFEU/ml);
ferritin (7-350 ng/ml); and lactate dehydrogenase (LDH) (100-242 Units/Liter). The
selected comorbidities can be found in Table 1 in the Discussion section. A more
thorough description of the attainment of the laboratory values can be found in Morrissey
et al. (2020). The clinical outcomes (discharge, mortality, and length of stay) were
monitored up to September 16, 2020.
2.3

Mass cytometry overview
Mass cytometry is a next generation flow cytometry platform which uses

elemental mass spectrometry to detect and quantify metal-conjugated antibodies that are
bound extracellularly and/or intracellularly to components of interests on single cells. 44
markers were used for the mass cytometry analysis depicted in the Appendix section in
9

Table A1. The description of the CyTOF mass cytometry sample preparation and data
acquisition for this study can be found in Morrissey et al. (2020). Here, we provide a
brief overview of how mass cytometry works.
Mass cytometry is where we take single cell dispersions and flow them into a
series of apparatuses that “burn” the cells and ionize the contents. Mass spectrometry is
then used to analyze the cells. In the first step of mass cytometry, cells are labeled with a
panel of metal-conjugated antibodies which can target cell surface markers, cellular
proteins, or other epitopes under investigation. The cells are then loaded into the mass
cytometer where they are injected through a nebulizer. The nebulizer orders the cells in a
single line and encases each one in a liquid droplet (Spitzer and Nolan, 2016). These cellcontaining droplets are sent to the inductively couple plasma (ICP) membrane where the
cells are ionized and burned. This generates a particle cloud created from the atoms of
each cell. Afterwards, the cells pass through a quadrupole mass filter where low atomic
mass atoms are separated from the high mass ions. The selected high mass ions then enter
the time of flight mass spectrometer. In the time of flight mass spectrometer is a detector
which quantifies the abundance of each heavy metal present on a per-cell basis. The raw
data collected by the detector are converted into an electrical signal which is analyzed by
the mass cytometry instrument software to identify cell events (Spitzer and Nolan, 2016).
Cell events are simply single cell readings. For each identified cell event, the signal
intensity in each channel is quantified and a Flow Cytometry Standard (.fcs) file, which is
used for analysis later, is generated from the data (Spitzer and Nolan, 2016).
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Figure 2. Workflow of mass cytometry. Key: A. Antibodies conjugated to metal isotopes;
B. Single-cell suspensions carried into nebulizer; C. Cells pass through a plasma torch; D.
Quadrupoles filter and purify ion clouds from the vaporized cells; E. Times of flight
(TOFs) of the ions are measured by a detector in the mass spectrometer; F. Individualized
cells are profiled by atomic mass; G. FCS file is created to store the information; H.
Analysis of the events using the .fcs file.

2.4

Gating strategy
Conventional flow cytometers and mass cytometers produce .fcs files that can be

manually analyzed using programs such as FlowJo and Cytobank, or computationally
using Bioconductor packages such as the flowCore package in R (Ellis et al., 2021). The
.fcs file is a data matrix in which every column represents a distinct isotope measured and
each row represents a single cell scan of the detector. Using FlowJo, we completed the
bottleneck step of analyzing CyTOF data – gating. Gating is the sequential identification
and refinement of a cellular population of interest using a panel of markers (Li et al.,
2017). It is performed via heat scatter plots such as those depicted in Figures 3 and 4,
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located at the end of this chapter, which illustrate our strategy. Warm zones colored red
and yellow represent a higher density of events, while cool zones colored blue and green
represent a lower density of events. In this study, our cellular populations of interest were
naïve and memory T cells.
Debris and dust can become trapped in the mass cytometer and result in pseudoevents. In addition, polystyrene beads are intentionally added to monitor the performance
of the mass cytometer. To distinguish the cells from debris, dust, and beads, Iridium-191
is used to tag DNA while beads are tagged with Cerium-140. In Figures 3 and 4, events
with high expression of the isotope are further right on the x-axis or upwards on the yaxis. We then gate on the cells.
From the cells, we select the live cells. Dead cells have compromised membranes
which allows to the cell marker cisplatin or Platinum-195 to react with the dead cells’
proteins. Thus, cells with high expression of cisplatin are dead. Unlike the other gating
selections, we select the cells with low expression of the marker or lower on the y-axis.
At times, cells will cohere to each other in the mass cytometer and be read as a
single event. Thus, we gate on true singlets or single cells. Singlet events are
characterized by shorter event lengths and less DNA in FlowJo.
Immune cells are characterized by the CD45 antigen. After gating on the CD45+
singlets, we have finished the “preprocessing” for gating on T cells and proceed to gate
for the naïve and memory T cells.
We distinguish T cells from other immune cells by selecting immune cells with
high expression of the CD3 antigen. From there, we can see two distinct sets of
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populations: CD4+ and CD8+ T cells. Finally, we gated on the CD4RO+ (memory T
cells) and CD45RA+ (naïve T cells) populations from CD4+ and CD8+ T cells.
2.5

CyTOF data analysis
In addition to FlowJo, CyTOF data was also analyzed using an R-based pipeline

from Bioconductor.org (Nowicka et al., 2017). Patients with observations in both
moderate and severe status were selected for clustering. Moderate was defined as
hospitalization without mechanical ventilation and severe was defined as hospitalization
and required mechanical ventilation. FlowJo workspace files were imported into RStudio
using the read.FCS function within flowCore (Ellis et al., 2021). An arcsinh
transformation with a cofactor of 5 was applied to the data using the “apply” function
within flowCore (Ellis et al., 2021). Diagnostic plots which included histograms of the
marker expressions and a principal component analysis plot were created. Cell population
clustering was conducted using FlowSOM (Gassen et al., 2015) and
ConsensusClusterPlus (Wilkerson and Hayes, 2010) within the Bioconductor CyTOF
workflow (Nowicka et al., 2017). A heatmap was then used to visualize the
characteristics of the identified cell clusters using the median marker expression in each
cluster. Last, t-SNE plots were used as a dimensionality reduction measure to examine
the CD4+ and CD8+ T cell populations.
2.6

Statistical analysis & modeling
The statistical analyses were carried out in the statistical software R

(https://www.r-project.org/). A statistical test was claimed significant if p < 0.05. First,
the five number summary statistics were presented for each appropriate variable.
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Percentages of patients were computed for comorbidities. This information is presented
in Table 1. PCA plots were created to characterize the patients by their comorbidities. For
feature selection, we examined the association among the variables using the marginal
Pearson correlation coefficient and tested its significance. The marginal Pearson
correlation coefficient captures the association between two variables at the population
level. Multiple imputations for the missing data were carried out using the mice package
(van Buuren S, 2011). Since we have varied number of observations for each patient and
an ordinal response variable, we applied cumulative link mixed models to the imputed
data sets. The clmm2 function within the ordinal package (Christensen, 2019) fit
cumulative link mixed models with random effects, where patients were considered
random effects. The results of each of the models were pooled using repeated imputation
inferences.
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Figure 3. Gating strategy for CD45+ immune cells. Panel A. Gate on cells using Beads
(y-axis) and DNA1 (x-axis); Panel B. Gate on live cells using Live (y-axis) and DNA1
(x-axis); Panel C. Gate on singlets using Length (y-axis) and DNA1 (x-axis); Panel D.
Gate on CD45+ cells (immune cells) using Length (y-axis) and CD45 (x-axis).
A.

B.

C.

D.

Notes: Warm zones, colored red and yellow, represent a higher density of events, while cool zones, colored blue and
green, represent a lower density of events. Population proportions of the total events displayed are indicated under the
gate names.
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Figure 4. Gating strategy for CD45RO+ and CD45RA+ T cells. Panel A. Gate on T cells
(CD3+) using Length (y-axis) and CD3 (x-axis); Panel B. Gate on CD8+ and CD4+ T
cells using CD8 (y-axis) and CD4 (x-axis); Panel C. Gate on CD45RA+ and CD45RO+
populations of CD8 T cells; Panel D. Gate on CD45RA+ and CD45RO+ populations of
CD4 T cells.
A.

C.

B.

D.
.

.

Notes: Warm zones, colored red and yellow, represent a higher density of events, while cool zones, colored blue and
green, represent a lower density of events. Population proportions of the total events displayed are indicated under the
gate names.
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CHAPTER III
CYTOF DATA ANALYSIS

3.1

Inspection of CyTOF data samples
When analyzing sample data, it is important to verify that the samples are

representative of the population. One way to check if this was true for the CyTOF data in
our study was to compare the moderate samples to the severe samples. To do this, we
took moderate and severe samples from patients who had both conditions at separate
points in time. These patients were patients 3, 4, 5, 8, and 37. In addition, we would need
to inspect if the marker expressions had any abnormalities, particularly inconsistent
ranges or dissimilar distributions for a subset of samples (Nowicka et al., 2017). These
could suggest issues with data collection or batch effects (Nowicka et al., 2017).
For the latter issue, histograms were created for the markers of the more
generalized cell populations frequently investigated, colored by the condition of the
patient during the draw. For the former, a principal component analysis (PCA) plot was
created to show the relationships between samples based on marker expressions. PCA is
an unsupervised dimensionality-reduction method that transforms a set of n-dimensional
vector samples 𝑋 = {𝑥1 , 𝑥2 , … , 𝑥𝑚 } into another set 𝑌 = {𝑦1 , 𝑦2 , … , 𝑦𝑚 } of the same
dimensionality (Kantardzic, 2020, p. 80). However, Y contain most of the information in
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the first few dimensions - the principal components (Kantardzic, 2020, p. 80). Thus, we
can reduce the dimensions of the data with a low loss of information (Kantardzic, 2020,
p. 80). The technique can be summarized in 6 steps. First, we remove the labels from the
data set (i.e. patient ID and draw number, condition). Next, we use the mean from every
dimension of the new data set to compute the covariance matrix. The eigenvectors and
corresponding eigenvalues of the covariance matrix are then computed. Afterward, we
select j eigenvectors with the j largest eigenvalues to form a n×j dimensional matrix A,
where n is the dimension of the original samples (Kantardzic, 2020, p. 80). Finally, A is
used to transform X into Y. The resultant PCA plot is shown in Figure 6. The first
notable observation is that there was less variation between moderate samples than the
severe samples. The second notable observation is that, with the exception of patient 4 at
draw 1, there is clear separation of the moderate vs. severe samples. This demonstrates
what we expect globally: there is a difference in marker expressions and thus immune
cell populations between moderate and severe cases of COVID-19.
Figure 5. Distributions of cell marker expression
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Figure 6. Principal component analysis plots of patient sample
A.

B.
.

.

Notes: The PCA plots are the same. Panel A includes the patient labels (P) and draw (D). Moderate observations are
blue and severe observations are orange.

3.2

T cell population identification
Two disadvantages of manual gating are bias from the scientist and obscure

separation of populations in the density plots. The FlowSOM and ConsensusClusterPlus
packages from Bioconductor.org employ clustering techniques to help eliminate these
concerns (Nowicka et al., 2017). Thus, we considered a cross-check necessary.
In the first step of FlowSOM, the data is read and preprocessed. The samples are
combined into one data matrix with the markers serving as the columns and the events as
the rows. The values for each column are scaled according to Z score normalization.

𝑧𝑖𝑗 =

𝑐𝑖𝑗 − 𝑚𝑒𝑎𝑛(𝑐1𝑗 , … , 𝑐𝑛𝑗 )
𝑠𝑡𝑑𝑒𝑣(𝑐1𝑗 , … , 𝑐𝑛𝑗 )

With this transformation, each column now has a mean of 0 and a standard deviation of 1
(Gassen et al., 2015). Now, each marker will hold the same weight in subsequent steps
while the differences between ranges within the markers have still been preserved.
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A self-organizing map (SOM) is then created using the function BuildSOM. Like
PCA, a self-organizing map is an unsupervised clustering technique that performs
dimensionality reduction. In this artificial neural network, cells are assigned according to
their likeness to 100 grid points of the SOM using an algorithm. The algorithm is as
follows: we have 100 d-dimensional nodes or “neurons”. We initialize the nodes with
random cells of the dataset (Gassen et al., 2015). We use the Chebyshev distance to
define a neighborhood function in the two-dimensional network (Gassen et al., 2015).
𝑑𝑖𝑠𝑡(𝐴, 𝐵) = max (|𝑥𝐴 − 𝑥𝐵 |, |𝑦𝐴 − 𝑦𝐵 |)
The SOM then learns in an iterative fashion. Data points are recursively selected and
matched to the nearest node. The nearest node, termed the Best Matching Unit (BMU),
and its neighborhood of nodes are moved closer to the data point. Neighbors that are
farther away will shift less. The distance moved by the BMU is the learning rate, α, and
the radius of the BMU is the size of the neighborhood, ε (Gassen et al., 2015). These are
decreased as the algorithm iterates (Gassen et al., 2015). Upon conclusion of the
algorithm, each cell is assigned to the node it most resembles which provides the final
clustering (Gassen et al., 2015).
Figure 7. Self-organizing map algorithm
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Lastly, meta-clustering of the SOM grid points is completed by the
ConsensusClusterPlus function utilizing consensus hierarchical clustering. This method
works by subsampling the points repeatedly and generating a hierarchical clustering for
each subsampling (Gassen et al., 2015). The frequency with which the same points are
clustered together is then used to determine the final clustering (Gassen et al., 2015).
There are two categories for hierarchical clustering algorithms: divisible
algorithms and agglomerative algorithms. A divisible algorithm starts from the entire data
set and divides the set into a partition of subsets. These subsets are divided into smaller
sets, and so on. In an agglomerative approach, each data point or node center is its own
initial cluster. The two closest clusters are identified and merged into one cluster. As the
process repeats, the clusters are merged into broader divisions and continue to
“agglomerate” until all objects are grouped into one cluster. Divisible algorithms could
be thought of as top-down approaches while agglomerative algorithms could be
considered bottom-up approaches.
Average linkage, a type of agglomerative approach, was used by
ConsensusClusterPlus to create the hierarchical clusters. In average linkage, we utilize
the mean inter-cluster dissimilarity by computing all pairwise distances between the
observations, x, in cluster A and cluster B and recording the average.
𝑛 𝑎 𝑛𝑏

𝐿(𝑟, 𝑠) =

1
∑ ∑ 𝐷(𝑥𝑎𝑖 , 𝑥𝑏𝑗 )
𝑛𝑎 𝑛𝑏
𝑖=1 𝑗=1

Euclidean distance defined below served as the distance measure between points:
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𝑛

𝑑𝑖𝑠𝑡(𝐴, 𝐵) = √∑(𝑎𝑖 − 𝑏𝑖 )2
𝑖=1

We can then specify the number of clusters and ConsensusClusterPlus function
will cut the computed hierarchical clustering tree - the dendrogram - at the appropriate
dissimilarity level, forming a partition. The selected number of clusters was 10. The
hierarchical clustering map is depicted in Figure 9.
Figure 8. Hierarchical clustering algorithm

T-distributed stochastic neighbor embedding (t-SNE) is a powerful tool to visualize and
explore single cell data. Cells in similar local neighborhoods of a high-dimensional space
are clustered together in a low-dimensional space, usually two-dimensional. These
clusters are then identified as specific cell types such as T cells, B cells, and neutrophils,
among others. T-SNE is typically preferred over PCA for single cell analysis because, as
Kobak and Berens (2019) state, it preserves the local structure better. We are more
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interested in clustering cells with high similarity, indicating a cell population, than the
distance between cell populations. For the latter component, the global structure of the
data, t-SNE performs worse than PCA (Kobak and Berens, 2019).
Figure 9. Heatmap of cell marker expression

Notes: the heatmap is colored according to the median of the arcsinh transformed values in the clusters. Higher
medians are red, lower medians are blue.

In the first step of t-SNE, the algorithm computes the similarities between points
in the high dimensional space. Similarity between two points of the data is the
conditional probability that xi would select xj as its neighbor if neighbors were picked in
proportion to their probability under a Gaussian centered at xi (Van der Maaten and
Hinton, 2008). These probabilities are then renormalized by dividing by the probabilities
of xi to all xj.

𝑝𝑗|𝑖

exp (−||𝑥𝑖 − 𝑥𝑗 ||2 /2𝜎𝑖2 )
=
,
∑𝑘≠𝑖 exp (−||𝑥𝑖 − 𝑥𝑗 ||2 /2𝜎𝑖2 )
∑ 𝑝𝑗|𝑖 = 1
𝑗
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𝑎𝑛𝑑

Now, pi|j ≠ pj|i so we define

𝑝𝑖𝑗 =

𝑝𝑗|𝑖 + 𝑝𝑖|𝑗
2𝑁

The second step is similar to the first step. However, instead we use a Student tdistribution with a single degree of freedom, also known as the Cauchy distribution. Van
der Maaten and Hinton (2008) discuss that the Student t-distribution has greater kurtosis,
or heavier tails, than the Gaussian distribution. This reduces crowding and allows for
better modeling of highly separated points. The result is a second set of probabilities, Qij,
in the low dimensional space:

𝑄𝑖𝑗 =

(1 + ||𝑦𝑖 − 𝑦𝑗 ||2 )−1
∑𝑘 ∑𝑙≠𝑘(1 + ||𝑦𝑖 − 𝑦𝑗 ||2 )−1

In the final step of the algorithm, we minimize the Kullback-Leibler divergence
between the conditional probabilities using gradient descent.
𝑝

𝐾𝐿(𝑃 || 𝑄) = ∑𝑖≠𝑗 𝑝𝑖𝑗 𝑙𝑜𝑔 𝑞𝑖𝑗
𝑖𝑗

With this, as Kobak and Berens (2019) affirm, the set of probabilities from the lowdimensional space, Qij, are made to reflect those of the high-dimensional space, Pij. From
this optimization, the locations of the cells in the low dimension are used for
visualization.
We can use a collection of markers to highlight where cell types of interest are
located on the t-SNE map. The t-SNE maps in Figure 10 are colored according to the
expression level of their respective marker. With consultation from an immunologist,
clusters 3 and 4 and were identified to be CD8 and CD4 T cells, respectively. The
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heatmap shows that that these populations formed 3.72% and 8.86% of the immune cells.
These values were cross checked with the gates obtained from the analysis in FlowJo.
With some variation, our percentages were consistent with the clustering.
Figure 10. T-SNE plots of the sampled cell populations. Panel A. CD3+ cells are
indicated at the upper portion of the t-SNE plot; Panel B. CD4+ cells (cluster 4) are in the
upper right portion of the t-SNE plot; Panel C. CD8+ cells (cluster 3) are in the upper left
portion of the t-SNE plot; Panel D. Clusters 3 and 4 are identified as the CD8+ and CD4+
T cells, respectively.
A.
B.

C.

D.

Notes: Figures10A – 10C are colored according to the arcsinh transformed values. Higher expressions are red/yellow,
lower expressions are blue. Figure 10D colors the cells by the formed clusters.
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CHAPTER IV
STATISTICAL ANALYSIS

4.1

Comorbidity selection
High-dimensional data can contain a substantial amount of irrelevant information.

In statistics, we call this information “noise”. Noise can lower the quality of the analysis
and contributes to the “curse of dimensionality”. It can also lead to overfitting of a model
when it is taken as concept to be learned by the algorithm and, thus, the model will fail to
generalize to the population or other data sets as well. Finally, with the inclusion of
additional variables, this further decreases the comprehensibility of the model.
There were 262 comorbidity factors within the clinical data, where 1 indicates
presence of a certain comorbidity and 0 indicates absence of the comorbidity. To reduce
noisy variables, comorbidities with less than a count of two for all patients were
automatically excluded from the data. This left a total of 88 comorbidity factors. We
further reduced the number of comorbidities by excluding those present in only 5% or
less of the patients. The comorbidities at the end of the selection were diabetes,
hypertension, hyperlipidemia, coronary artery disease, COPD, asthma, and obstructive
sleep apnea. We use the 88 comorbidities and the final selected comorbidities to illustrate
the dimension reduction with Multiple Correspondence Analysis (MCA).
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Although PCA could be used for dimension reduction, PCA is used on continuous
variables. MCA is used for categorical or nominal variables. Greenacre and Nenadic
(2015) explain the attainment of the principal coordinate using the Burt matrix. In MCA,
each factor, K, has Jk levels where ∑k Jk = J. We denote the index of 𝑖 as the 𝑖 𝑡ℎ
observation. So then, Z = {zij} is the indicator matrix for the comorbidities. B is the Burt
matrix and is acquired from B = ZTZ (Greenacre and Nenadic, 2015). To complete the
MCA, there are 4 following steps. In the first step, we compute the correspondence
matrix P by dividing B by its grand total 𝑛 = ∑𝑖,𝑗 𝑏𝑖𝑗 (Greenacre and Nenadic, 2015):

𝑃 = {𝑝𝑖𝑗 } = {

𝑏𝑖𝑗
}.
𝑛

We also compute the row totals ri.
Second, an eigenvalue-eigenvector decomposition is completed on standardized
residuals, S (Greenacre and Nenadic, 2015):
𝑆 = {𝑠𝑖𝑗 } =

𝑝𝑖𝑗 − 𝑟𝑖 𝑟𝑗
√𝑟𝑖 𝑟𝑗

.

The decomposition returns the eigenvectors, E = {eis}, and eigenvalues 𝜆𝑠 from the
solution of S = VΛVT (Greenacre and Nenadic, 2015).
The 𝑖th row (or column) standard coordinate for the 𝑠th dimension is obtained as
𝑎𝑖𝑠 =

𝑣𝑖𝑠
√𝑟𝑖

Finally, Greenacre and Nenadic (2015) state that principal coordinates from MCA can be
obtained from
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𝑓𝑖𝑠 = 𝑎𝑖𝑠 𝜆𝑠
The quality of the representation is measured by the squared cosine (cos2). The squared
cosine measures the degree of association between the factors or individuals in the MCA
plot and the two dimensions. The squared cosine is calculated by dividing the absolute
contribution to an axis by the sum of its absolute contribution to all axes in the analysis.
The squared cosine for row and columns, respectively, are

𝜃2 =

𝑓𝑖𝑙2
𝑔𝑖𝑙2
2
and
𝜃
=
∑ 𝑓𝑖𝑙2
∑ 𝑔𝑖𝑙2

where we have row 𝑖, column 𝑗, and factor 𝑙 (Salkind, 2010).
Comparing the variables squared cosine plots in Figure 10, many of the 88
comorbidities overlapped and did not provide much contribution (if any) to the
dimensions. Using the 7 selected comorbidities, there were higher contributions on
average from each of the variables. Both plots appear to be separated into two halves:
absence of comorbidities on the left and the presence of comorbidities on the right.
Examining the individuals MCA plots, we see three clusters of patients from the updated
group of comorbidities that were not visible using the 88 comorbidities: those without
hypertension or diabetes (red), those with hypertension and diabetes (orange), and those
with a different combination of the two that separates them from the former two (blue).
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Figure 11. Multiple correspondence analysis, contribution, and squared cosine. Panel A.
PCA map of the 88 comorbidities; Panel B. PCA map of the 7 selected comorbidities;
Panel C. PCA map of the patients using the 88 comorbidities; Panel D. PCA map of the
patients using the 7 selected comorbidities.
A.

B.

C.

D.

Notes: Variables and individuals are colored according to the cos2 values. Red signifies a higher cos2 while blue
signifies a lower cos2. A sum of cos2 close to one means a variable or patient is well represented by the two
dimensions.

4.2

Correlations
Multicollinearity is the occurrence of significant dependency or association

between two or more independent variables (Kim, 2019). A high intercorrelation between
predictor variables is indicative of multicollinearity in the data. Multicollinearity can
produce skewed results which result in erroneous interpretations of the data. Though
some models can account for multicollinearity and will remove one of the correlated
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variables (Kim, 2019), computing the correlations between the independent variables is
often one of the first steps in data analysis. To avoid multicollinearity influencing the
model in our study, Pearson’s correlations were computed.
Pearson’s correlation measures the strength of the linear relationship between a
pair of variables (Kirch, 2008). For Pearson's correlation coefficient, the null hypothesis
is that the correlation between a pair of variables, ρ, is equal to 0 and the alternative
hypothesis is that the correlation is not equal to 0.
H0 : ρ = 0 vs. 𝐻1 : ρ ≠ 0
The correlation coefficient assumes a value between −1 and +1. If one variable trends
towards decreasing as the other increases, the correlation coefficient is negative.
Conversely, if the two variables tend to increase conjunctively the correlation coefficient
is positive. The closer the correlation coefficient is to -1 or +1, the stronger the trend. For
the variables x and y, the correlation statistic, r, is calculated by:

𝑟=

∑𝑛𝑖=1(𝑥𝑖 − 𝑥̅ )(𝑦𝑖 − 𝑦̅)
√(∑𝑛𝑖=1(𝑥𝑖 − 𝑥̅ )2 √(∑𝑛𝑖=1(𝑦𝑖 − 𝑦̅)2

where n is the number of observations with values of xi and yi for the 𝑖th individual
(Mukaka, 2012).

The p-value of a statistical test is the probability of obtaining test results equally
or more extreme than the observed results under the condition that the null hypothesis is
correct (Greenland et al., 2016). In other words, it is the probability that an observed
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difference could have occurred just by random chance. The p-value for Pearson's
correlation coefficient uses the t-distribution (Park, 2014).

𝑡=

𝑟√𝑛 − 2
√1 − 𝑟 2

The p-value is obtained as 2 × P(T > t), where T follows a t-distribution with n – 2
degrees of freedom. If the p-value is less than the α level, the threshold value used to
determine if a test statistic is statistically significant, we reject the null hypothesis and
accept the alternative hypothesis. If the p-value is greater than α level, we fail to reject
the null hypothesis.

The correlations within each of the subtypes of data were computed: laboratory
values, comorbidities, and CyTOF data. Several significantly large correlations were
found within the CyTOF data and a few within the laboratory values. Next, the interclass
correlations were calculated, comparing the CyTOF data with the comorbidities first, the
CyTOF data with the laboratory values second, and the comorbidities with the laboratory
values last. Variables which were highly correlated were identified. Variables with
clinical importance were retained while those with less importance or a larger proportion
of missing values were removed from further analysis. From this step, the variables
neutrophil count, IL-6, and c-reactive protein, a, d, f, and h were removed.
4.3

MICE imputation
As is common with clinical data, missing values were present for the lab values.

Simply discarding samples with missing data could have potentially reduced power and
biased model outputs (Kang 2013).
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There are three types of missing data and the type of missing data the data falls
under should be used to determine how the missing values are imputed. One of those
missing types of data is missing completely at random (MCAR). Data are MCAR when
the probability that values are missing is independent of the observed and unobserved
data (Mack et al., 2018). In other words, the cause that the data is missing is completely
random. An example would be unplanned exhaustion of laboratory instruments.
Classifying missing data as MCAR is a strong assumption with a strong probability of
being incorrect (Mack et al., 2018). Missing at random (MAR) is a weaker assumption
that states the missingness can be explained by some of the observed data (Mack et al.,
2018). For example, males might be less likely to participate in blood sampling to detect
white blood cells, however, this is not related to their white blood cell count. Finally,
missing data can be missing not at random (MNAR). MNAR data occur when the
probability that a variable is missing is related to value of the variable (Nakagawa, 2015).
For instance, participants with more severe depression are less likely to participate in a
survey asking them to rate their depression.
We believed the missing data to be MAR or MCAR, thus, we required a
technique that would be optimal for imputing the missing values. Multivariate Imputation
via Chained Equations (MICE) is a multiple imputation method that assumes that the
missing data are MAR. MICE takes a divide and conquer approach to imputing data in
which Azur et al. (2011) summarize in six steps.
Step 1.

The missing values in each variable are replaced with a temporary

“place holder”. This place holder is computed from a simple imputation
such as imputing the mean.
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Step 2.

MICE removes the placeholder values from one variable.

Step 3.

The observed values from the variable in step 2 are regressed on all

or part of the variables of the imputation model. Linear regression is the
default method for continuous missing variables; however, MICE can
predict other types of variables as well. Logistic regression is used for
binary categorical missing values, predictive mean matching (PMM) is
used for numeric variables, Bayesian polytomous regression is used for
categorical variables with at least 2 levels, and the proportional odds
model is used for ordered data with at least 2 levels. Table A2 shows the
imputation methods for the covariates in our models.
Step 4.

The regression model created in Step 3 is used to predict or

“impute” the missing values of the variable in Step 2. The newly
completed variable will be used as an independent variable in subsequent
regression models.
Step 5.

MICE repeats Steps 2 – 4 for every variable with missing data.

Each completion of Steps 1 – 5 is termed a “cycle”. Upon the conclusion
of a cycle, the missing values for the attended variable have been restored
with predictions from regression models that indicate the associations
observed in the data.
Step 6.

Multiple cycles (we can specify the number, n) are run and at the

end of each cycle, the imputed values are updated. The final values are
retained from the final cycle.
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After n cycles, one complete data set has been produced. The estimation of
parameters and their variance can be obtained based on the complete data set. For our
study, the final estimates of parameters and their variance will be based on repeated
imputed inferences (Rubin, 1996), introduced below.
Figure 12. MICE algorithm
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4.3

Repeated imputations inferences
If m complete data sets are produced, each completed data set can then be

analyzed to yield m completed-data statistics, which are usually model estimates, say 𝑄̂𝑙
̂𝑙 for l = 1,…, m.
for l = 1, …, m, and m associated variance-covariance matrices, say 𝑈
Using the repeated-imputation inferences, we are able to pool the 𝑚 models’ estimates
and determine the significance of the covariates. The repeated-imputation estimate is
𝑚

𝑄̅𝑚 = ∑ 𝑄̂𝑙 ⁄𝑚
𝑙=1

and the associated variance-covariance of 𝑄̅𝑚 is
̅𝑚 +
𝑇𝑚 = 𝑈

𝑚+1
𝐵𝑚
𝑚

Here, the within-imputation variability is given by
𝑚

̅𝑚 = ∑ 𝑈
̂𝑙 ⁄𝑚 ,
𝑈
𝑖=1

and the between-imputation variability is given by
𝑚
′
𝐵𝑚 = ∑(𝑄̂𝑙 − 𝑄̅𝑚 )(𝑄̂𝑙 − 𝑄̅𝑚 ) /(𝑚 − 1)
𝑖=1

The 𝑚 repeated-imputation inference takes (𝑄 − 𝑄̅𝑚 ) to be a random variable with
normal distribution and variance-covariance matrix 𝑇𝑚 . Thus, letting m = ∞
(𝑄 − 𝑄̅∞ ) ~ 𝑁(𝑂, 𝑇∞ ) ,
̅∞ + 𝐵∞ (Rubin, 1996).
where 𝑇∞ = 𝑈
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The Wald test statistic, W, can be calculated by

𝑊=

𝐵𝑚
√𝑇𝑚

Figure 13. Repeated imputations. Key: A. Original data set with missing data; B.
Imputed data sets; C. Regression equations from each of the imputed data sets; D. Pooled
regression model using repeated imputation inferences.

4.4

Cumulative link mixed model
A cumulative link mixed model was created for ordinal regression with clinical

outcome as the response variable.
Let 𝜋𝑖𝑗 = Pr{𝑌𝑖 = 𝑗 | 𝑋 = 𝑥𝑖 } the probability that the response of an individual i
with characteristics 𝑥𝑖 falls in the 𝑗 𝑡ℎ category and let 𝛾𝑖𝑗 denote the corresponding
cumulative probability.
𝛾𝑖𝑗 = Pr(𝑌𝑖 ≤ 𝑗 | 𝑋 = 𝑥𝑖 )
Equivalently,
𝛾𝑖𝑗 = 𝜋𝑖1 + 𝜋𝑖2 + … + 𝜋𝑖𝑗
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Now, define 𝐺 −1 () as the logit function of a probability, p.
𝐺 −1 = 𝑙𝑜𝑔𝑖𝑡(𝑝) = 𝑙𝑜𝑔 (

𝑝
)
1−𝑝

Then, the general form of the cumulative link model is
𝐺 −1 (𝛾𝑖𝑗 ) = 𝛼𝑗 − 𝑋𝛽,
where 𝛼𝑗 is a constant representing the threshold or intercept for level j and 𝛽 is the
vector of coefficients for each covariate.
The cumulative link regression model above assumes independence of the
observations. When multiple measures are derived from the same individual or across
time, as is the case with longitudinal analysis, this assumption is violated (Schmidt,
2012). In a cumulative link mixed model, a random effect is introduced to the cumulative
link model to account for dependent observations (Schmidt, 2012). The general form of
the cumulative link mixed model is
𝐺 −1 (𝛾𝑖𝑗 | 𝑋 = 𝑥𝑖 ) = 𝛼𝑗 − (𝑍𝑖 𝑢𝑖 + 𝑋𝑖 𝛽)
where 𝑍𝑖 and 𝑢𝑖 are the random effects design matrix and random effects, respectively,
for 𝑖 𝑡ℎ subject, and 𝑢𝑖 ~ 𝑁(𝑂, 𝜎𝑢2 ) (Schmidt, 2012). Together, 𝛽, 𝛼𝑗 , and, 𝑢𝑖 are the
complete-data estimates. Here, we are primarily interested in the parameters 𝛽 and 𝑢𝑖 ,
which are the 𝑄̂ in multiple imputation. We use the MICE package in R to form m
complete data sets, and for each complete data set we apply the cumulative link mixed
̂𝑙 ) for l = 1, …, m.
models to obtain the parameter estimates (𝑄̂𝑙 ) and their variance (𝑈
Further, we apply Rubin’s repeated imputations inference to obtain the final estimate 𝑄̅𝑚
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and its variance 𝑇𝑚 for inference about the importance of the predictive variables on the
clinical outcome.
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CHAPTER V
RESULTS

Table 1 displays the clinical characteristics, comorbidities, CyTOF T cell
population percentages, laboratory values at the time of observations as well as the
distribution of the clinical outcome in severity in scale from 1 to 5. The median age was
64 years old with IQR as [50; 73], 57% female, with median BMI of 31 and IQR [24; 40]
(Table 1). Comorbidities were present in most patients with diabetes (45.7%),
hypertension (65.7%), hyperlipidemia (8.6%), coronary artery disease (5.7%), asthma
(11.4%), and obstructive sleep apnea (11.4%) (Table 1). T cell population percentages
were acquired from every observation. The median percentages and their IQR were as
follows: CD4+CD45RA+ of T cells 21.3% [12.0%; 28.7%]; CD4+CD45RA+ of CD4+ T
cells 35.1% [21.8%; 46.9%]; CD4+CD45RO+ of T cells 25.2% [19.6%; 33.8%];
CD4+CD45RO+ of CD4+ T cells 47.7% [35.6%; 63.1%]; CD8+CD45RA+ of T cells
14.2% [8.0%; 18.7%]; CD8+CD45RA+ of CD8+ T cells 64.9% [49.2%; 78.0%]; and
CD8+CD45RO+ of CD8+ T cells 3.2% [2.1%; 7.1%]; CD8+CD45RO+ of T cells 17.8%
[8.0%; 18.7%] (Table 1). The study’s patients showed a deviation from normal ranges
within the available D-Dimer, Ferritin, C-reactive protein (CRP), Hgb, neutrophil
percentage, lymphocyte percentage, lactate dehydrogenase, interleukin 6, and P/F ratio
values. For these tests, the median was outside of the normal range (Table 1). Outcomes
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Table 1. Demographic characteristics, comorbidities, T cell population percentages,
clinical markers, outcome counts
Variable
Number of observations
Number of patients
Patient Characteristics
Age (y.o)
Gender (female) (%)
BMI (kg/m2)
Comorbidities (%)
Diabetes (DM)
Hypertension (HTN)
Hyperlipidemia (HLD)
Coronary Artery Disease (CAD)
Asthma
Obstructive Sleep Apnea (OSA)
CyTOF T Cell Populations (%)
CD4+CD45RA+ of T cells (a)
CD4+CD45RA+ of CD4+ T cells (b)
CD4+CD45RO+ of T cells (c)
CD4+CD45RO+ of CD4+ T cells (d)
CD8+CD45RA+ of T cells (e)
CD8+CD45RA+ of CD8+ T cells (f)
CD8+CD45RO+ of T cells (g)
CD8+CD45RO+ of CD8+ T cells (h)
Laboratory Values
D-Dimer (miss = 59) (µgFEU/mL)
Ferritin (miss = 60) (ng/mL)
CRP (miss = 61) (mg/L)
WBC (miss = 4) (× 103/µL)
Hgb (miss = 4) (gram/dL)
Platelet (miss = 4) (× 103/µL)
Neutrophil % (miss = 35)
Neutrophil Count (miss = 56) (× 103/µL)
Lymphocyte % (miss = 36) (/µL)
Lymphocyte Count (miss = 50) (× 103/µL)
LDH (miss - 68) (units/L)
IL-6 (miss = 107) (pg /mL)
Creatinine (miss = 22) (mg/dL)
P/F Ratio (miss = 55)
Outcomes
Discharge (1)
To floor/Extubation (2)
To ICU (3)
Intubation (4)
Death (5)

Value
112
35

Normal Range

64 [50; 73]/(28|95)
20 (57)
31 [24; 40]/(18|54)
16 (45.7)
23 (65.7)
3 (8.6)
2 (5.7)
4 (11.4)
4 (11.4)
21.3 [12.0; 28.7]/(1.8|51.8)
35.1 [21.8; 46.9]/(12.4|65.3)
25.2 [19.6; 33.8]/(5.6|49.9)
47.7 [35.6; 63.1]/(18.9|75.7)
14.2 [8.0; 18.7]/(1.1|41.8)
64.9 [49.2; 78.0]/(21.0|89.1)
3.2 [2.1; 7.1]/(.2|21.6)
17.8 [8.0; 18.7]/(1.1|41.8)
2.3 [.87; 6.4]/(.21|32.0)
385 [279.5; 729.2]/(17|6231.0)
115.3 [51.1; 175.8]/(7.1|439.2)
8.9 [5.9; 12.1]/(1.0|25.5)
9.9 [8.3; 11.4]/(6.6|14.5)
228.5[158.0; 298.5]/(28.3|595.0)
74 [64.8; 82.2]/(5.0|94.2)
5.3 [2.9; 7.2]/(1.5|18.1)
13.3 [8.4; 21.6]/(3.8|36.6)
.8 [.3; 1.2]/(0.0|2.6)
318.5 [225.0; 443.2]/(104.0|729.0)
62.3 [46; 77]/(24.6|126.2)
1.2 [.74; 1.9]/(.4|6.2)
180.0 [111.0; 226.7]/(52.0|310.0)
5
39
14
53
1

Notes: Data are expressed as medians [Interquartile IQ] or (min|max).
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.19 - .74
7 - 350
0.0 - 10.0
4.1 - 10.8
13.7 - 17.5
140 - 370
40 - 60
1.56 – 6.45
20 - 40
0.95 – 3.07
100 - 242
5 - 15
.59 - 1.35
≥ 400

were evaluated the day of the blood samples for CyTOF data. For clinical outcomes, 5
observations were discharge, 39 observations were on the floor or extubated, 14
observations were in the ICU, and 1 observation occurred on the same day of death
(Table 1).
Pearson correlations were computed using the pairwise complete observations.
That is, for any two pair of variables, the observations with complete data for the
variables of interest were used to calculate the correlation. Significant (p <.05) Pearson
correlations with an absolute value of r greater than or equal to .7 were selected for
during feature selection. The significant (|r| > .7, p < .05) results of the Pearson
correlation computations are in Table 2.
We found significant correlations within two categories of the data. Within the
laboratory values, an increase in white blood cell count (WBC) was highly associated
with an increase in Neutrophil count (r = .98, p < .05), IL-6 had a strong positive
correlation with LDH (r = .99, p < .05), and CRP was inversely correlated with P/F ratio
(r = -.78, p < .05) (Table 2). The clinical marker with the highest percentage of complete
data was selected for inclusion within the final model. Within the CyTOF data, increases
in the T cell percentages of CD4+CD45RA+ T cells (a) were associated with increases in
CD4+ T cell percentages of CD4+CD45RA+ T cells (b) (r = 0.89, p < .05) (Table 2).
Increases in the CD8+ T cell percentages of CD8+CD45RO+ T cells (h) were associated
with increases in the T cell percentages of CD8+CD45RO+ T cells (g) (r = .74, p < .05)
(Table 2). The following were negatively correlated: T cell percentages of
CD4+CD45RA+ T cells (a) with CD4+ T cell percentages of CD4+CD45RO+ T cells (d)
(r = -.86, p < .05), CD4+ T cell percentages of CD4+CD45RA+ T cells (b) with T cell
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percentages of CD4+CD45RO+ T cells (c) (r = -.97, p < .05), CD8+ T cell percentages of
CD8+CD45RA+ T cells (f) with T cell percentages of CD8+CD45RO+ T cells (g) (r = .71, p < .05), and CD8+ T cell percentages of CD8+CD45RA+ T cells (f) with CD8+ T
cell percentages of CD8+CD45RO+ T cells (h) (r = -.97, p < .05) (Table 2). Essentially,
there were two groups of high correlation with 3 variables within each. The variable with
the highest average absolute value of r within each group was selected for inclusion
within the final model. These were variables b and g.
Table 2. Significantly correlated variables
Variable 1
WBC
IL-6
CRP
a
a
b
f
f
g

Variable 2
Neutrophil Count
LDH
P/F Ratio
b
d
d
g
h
h

Correlation P-value
0.98
0.00
0.99
0.04
-0.71
0.00
0.89
0.00
-0.86
0.00
-0.97
0.00
-0.71
0.00
-0.97
0.00
0.74
0.00

The estimates, standard errors, Wald test statistics, and p-values from repeated
imputation inferences utilizing the cumulative linked mixed models are depicted in Table
3. BMI, Hgb, and the CD4+CD45RA+ T cells percentage of CD4+ T cells were found to
be significant predictors (p < .05) of clinical outcome with estimates of .27, -1.39, and
.06, respectively. At the significance level of .10, this group also includes WBC, HLD,
and the CD4+ T cells percentage of CD4+CD45RA+ T cells with estimates of .42, 9.05,
and .06, respectively. From the model
𝐺 −1 (𝛾𝑖𝑗 ) = 𝛼𝑗 − (𝑍𝑖 𝑢𝑖 + 𝑋𝑖 𝛽),

42

positive coefficients lead to an increase in the probability of higher-level categories.
Thus, increased levels of covariates with a positive coefficient were associated with
worse clinical outcomes. From the covariates with significant p-values, an increase in
BMI and the percentage of CD4+ T cells composed of CD4+CD45RA+ T cells signified
a poorer clinical outcome. Conversely, an increase of covariates with negative
coefficients lead to a decrease in the probability of higher-level categories. From the
covariates with significant p-values, an increase in Hgb levels was associated with better
clinical outcomes.
The thresholds (e.g., 1|2, 2|3, 3|4, 4|5) are intercepts for each of the ordinal levels
in the cumulative link mixed model. Under the proportional odds assumption, these are
assumed to be constant for all values of the remaining independent variables.
Random effect generates the correlation expected between observations from the
same patient and allows inferences to be made to the population from which the groups
were sampled. Negligence to consider the correlations of within patient observations
could have resulted in biased estimates and invalid statistical inferences. Thus, we took
the patient effects to be random and assumed that the patient effects were independent
and identically distributed normal: 𝑢(𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑖 ) ~ 𝑁(𝑂, 𝜎𝑢2 ).
One method of determining if a variable should be treated as a random effect is
the intraclass correlation (ICC) (Theobald, 2018). The ICC is the measure of the
clustering in a variable and is given by
𝜎𝑢2
𝐼𝐶𝐶 = 2
𝜎 + 𝜎𝑢2
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Here, 𝜎 2 represents the residual variance, which is assumed to be one in
cumulative link mixed models. 𝜎𝑢2 represents the variance of the random effect (Schmidt,
2012), 7.655 from the model. When ICC = 0, there is no clustering, i.e., observations
within a given patient are just about independent. When ICC = 1, there is complete
clustering (Theobold, 2018), i.e., observations within a given patient from the study were
highly similar. The ICC was .88, thus, patient should be treated as a random effect as a
patients’ clinical outcomes from COVID-19 were highly correlated.
Table 3. Pooled model estimates which include patient as random effect
1|2
2|3
3|4
4|5
BMI
WBC
Hgb
Platelet
Creatinine
HTN
DM
HLD
CAD
Asthma
OSA
b
c
e
g
random effect

Estimate
-16.06
-3.25
-0.89
15.40
0.27
0.42
-1.39
0.00
0.63
0.67
-3.34
9.05
0.6
5.02
0.62
0.06
-0.02
-0.16
-0.42
7.655

Std. Error
5.58
4.96
4.82
6.75
0.13
0.23
0.596
0.01
1.24
2.16
2.36
5.22
6.35
4.18
4.40
0.03
0.04
0.10
0.11
2.96

z value
-2.88
-0.66
-0.18
2.28
2.08
1.83
-2.33
0.00
0.51
0.31
-1.42
1.73
0.09
1.20
0.14
2.00
-0.50
-1.60
-3.82
2.59

Pr(>|z|)
0.00
0.51
0.85
0.02
0.04
0.06
0.02
0.74
0.61
0.76
0.16
0.08
0.99
0.23
0.89
0.05
0.71
0.11
0.00
0.01

Notes: Table 3 is produced from 10 sets of estimates reported in the appendix in Table A3. Each set of estimates was
obtained from an imputed data set.
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CHAPTER VI
DISCUSSION

6.1

Observations
The study’s patients showed a deviation from normal ranges within the available

D-Dimer, Ferritin, C-reactive protein (CRP), Hgb, neutrophil percentage, lymphocyte
percentage and count, lactate dehydrogenase, interleukin 6, and P/F ratio values. For
these tests, the median was outside of the normal range (Table 1).
D-dimer is a protein fragment produced when a blood clot is dissolved in the body
and, as a clinical marker, is used to monitor coagulation state. High levels of D-dimer in
the blood indicate a major clot like deep vein thrombosis (DVT). Our increased levels of
D-dimer compared to normal D-dimer ranges suggests a higher risk of thrombosis in
COVID-19 patients. Similarly, Yao et al. (2020), concluded that D-dimer levels are
commonly elevated in COVID-19.
Ferritin is a blood protein that stores iron that is used to monitor systemic
inflammation. One explanation for the high levels for elevated Ferritin in COVID-19
patients is that the natural immune response might limit iron turnover during infections to
prevent pathogens from using it (Bozkurt et al., 2021). Elevated ferritin levels have been
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shown to be a characteristic of severe COVID-19 patients in several studies (Banchini et
al., 2021; Vargas-Vargas and Cortés-Rojo, 2020).
An Hgb test measure how much hemoglobin red blood cells contain. Hgb helps
red blood cells transport oxygen from the lungs to the body. Opposite of many of the
clinical markers, Hgb was lower than normal ranges for study’s patients. This concurs
with a study by Dinevari et al. (2021) study which showed a high prevalence of anemia in
hospitalized patients with COVID-19.
Neutrophils and Lymphocytes are both types of white blood cell types.
Lymphopenia (Jafarzadeh et al., 2021) and high neutrophil (Huang et al., 2020) counts
have been characteristic of COVID-19 patients. In addition, a higher level of neutrophileto-lymphocyte (i.e. a higher neutrophil percentage) has been linked to severe COVID-19
(Kong et al., 2020).
Increased levels of LDH in the blood, as seen in this study, signify early-stage
myocardial infarction and hemolysis (Szarpak et. al, 2020). Szarpak et al. (2020) and
Henry et al. (2020) found LDH levels to be markers of COVID-19 severity and predictors
of survival.
Interleukin 6, or IL-6, is one of the overproduced inflammatory proteins, called
cytokines, that are associated with a condition known as cytokine release syndrome or
cytokine storm (Jose and Manuel, 2020). Cytokine storms, if not de-escalated, lead to
increased chance of vascular hyperpermeability, multi-organ failure, and death (Jose and
Manuel, 2020). As in our study, IL-6 levels have been shown to be elevated in the
peripheral blood of COVID-19 patients (Chen et al., 2020).
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P/F ratio is an oxygenation index used to identify hypoxia and respiratory distress.
However, its use for this purpose is controversial (Tobin et al. 2021, Gu et al., 2021) so
we will avoid further discussion on this subject.
For the correlations, neutrophils are a type of white blood cell, so it was
reasonable that a strong, significant correlation was detected. Our study results align with
Ede et al. (2013) in that there was a positive correlation between LDH and IL-6. IL-6 is a
cytokine that mediates inflammation whereas LDH is the product of inflammatory injury.
This correlation makes sense. C-reactive protein and P/F ratio were inversely correlated;
however, once again, we will avoid any discussion on P/F ratio due to its controversial
usage. Finally, there were several correlations between the CyTOF T cell population
percentages. This was expected as an increase one population’s percentage would
guarantee a decrease in another’s. We believed it important to show the percentages of
complementary populations to gain a holistic view of the T cells and then select the
percentages to be used for the model. Ultimately, the CD4+ T cell percentages of
CD4+CD45RA+ T cells and the CD8+ T cell percentages of CD8+CD45RO+ T cells
were used.
The cumulative link mixed model determined BMI, Hgb, and CD8+ T cell
percentages of CD8+CD45RO+ T cells to be significant predictors of COVID-19
severity. The BMI and Hgb factors significance is in agreement with several other
studies. Hendren et al. (2020) and Dinevari et al. (2021) are just two examples. Our
model supports a hypothesis that an increase in the percentage of memory CD8+ T cells
over T cells overall was associated with improved clinical outcomes.
6.2

Limitations
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There were only 112 observations and 35 patients. In addition to this being low
sample size of the dataset, with an average of 3.2 observation per patient, there were few
observations from each patient. Cumulative link model estimates can be unstable if there
are a small number of observations within clusters or if there are few clusters from which
to estimate within group correlation (Schmidt, 2012). Furthermore, only 1 observation
had the outcome of the death. In general, a small sample size reduces the confidence level
of any study and reduces the statistical power, the ability to detect an effect when there is
one to be detected. It could very well be that other covariates in our model were
significant predictors, but due to small sample size and inappreciable effect, the model
was not able to detect these associations.
Another limitation of this study was the missing data within the laboratory values.
This caused us to exclude several potentially significant covariates from our model.
Although we were able to perform multiple imputation, imputed data holds less value
than observed data. The values imputed were regressed only with the covariates included
in the model. Though we selected covariates commonly measured in COVID-19 studies,
an incorrectly chosen conditioning set can make the imputations endogenous and lead to
bias (Mittag, 2013). There were other variables that would have been better to impute
values for. This is why in addition to utilization of the repeated imputation inferences, to
counter any potential errors in imputation, we selected laboratory values with less than
20% of the data missing.
There were 262 potential comorbidities that could have been included in the data.
However, over half of these were excluded due to occurrence in only 2 or fewer patients.
These were potential explanators of laboratory values in multiple imputation or COVID
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severity in the cumulative link mixed models as well. However, to simplify the model
and due a likely outcome of insignificance because of low sample size, we chose to
exclude these values.
When individuals in a longitudinal study have the same number of repeated
measurements collected in similar time intervals, the study is considered to be
“balanced”. Time between a draw and the previous one varied in the data.
Although cross-checked with manual and computational methods, it is unlikely
that we obtained the exact percentages of the T cell population for every observation.
Errors are almost bound to occur when manual gating. Divisions and selections of the
populations is subjective to the scientist doing the gating. Nevertheless, we believe these
values to be close to the true values after thorough review from multiple individuals and
experts.
6.3

Future studies
Our longitudinal study found BMI, Hgb, and CD8+ T cell percentages of

CD8+CD45RO+ T cells to be significant predictors of COVID-19 severity. However, the
physiological pathways and cellular etiology of COVID-19 involves more than just T
cells and hemoglobin. Potential future studies of our work could look at the interaction of
of CD8+CD45RO+ T cells with other cell populations and how this affects COVID-19
severity. Furthermore, we propose more extensive longitudinal testing to characterize the
effect of COVID-19 infection after discharge from the hospital. This would provide a
more comprehensive perspective of infection over time.
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APPENDIX
7.1 Supplementary Tables
Table A1. Mass cytometry antibody panel
Antigen
CD16
CD8
CD14
CD4
CD11b
CD3
CD20
CD19
CD80
CD79b
CXCR3
CXCR5
CD44
CD27
CD40L
CTLA-4
LAMP1
gdTCR
CD56
CD86
TLR4
CD28
CD45RA
CD274
CD40
CD123
CD69
CD163
IgD
CD66b
LAG-3
CD196
CD11c
CD45RO
CD21
TIM-3
CD197
CD25
CD45
CD68
CD38
HLA-Dr
CD279
CD127

Symbol & Mass
Bi209
Cd106
Cd110
Cd111
Cd112
Cd113
Cd114
Cd116
Dy161
Dy162
Dy163
Dy164
Er166
Er167
Er168
Er170
Eu151
Eu153
Gd155
Gd156
Gd158
Gd160
Ho165
Lu175
Nd142
Nd143
Nd144
Nd145
Nd146
Nd148
Nd150
Pr141
Sm147
Sm149
Sm152
Sm154
Tb159
Tm169
Y89
Yb171
Yb172
Yb173
Yb174
Yb176

Antibody Clone
3G8
RPA-T8
M5E2
RPA-T4
IRCF44
UCHT1
2H7
HIB19
2D10.4
CB3-1
G025H7
RF8B2
BJ18
L128
24-31
14D3
H4A3
B1
HCD56
IT2.2
HTA125
CD28.2
HI100
29E.2A3
5C3
6H6
FN50
GHI/61
IA6-2
G10F5
11C3C65
G034E4
Bu15
UCHL1
BL13
F38-2E2
G043H7
2A3
HI30
Y1/82A
HIT2
L243
EH12.2H7
A019D5
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Source
Fluidigm
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Biolegend
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Biolegend
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Biolegend
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm

Table A2. Method of imputation
Method
BMI
""
HLD
""
g
""

WBC
"pmm"
CAD
""

Hgb
"pmm"
Asthma
""

Platelet
"pmm"
OSA
""

Creatinine
"pmm"
b
""
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HTN
""
c
""

DM
""
e
""

Table A3. Coefficients of Cumulative Link Mixed Models
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1|2
2|3
3|4
4|5
BMI
WBC
Hgb
Platelet
Creatinine
HTN
DM
HLD
CAD
Asthma
OSA
b
c
e
g
random effect

1
-15.71053
-2.99596
-0.67670
15.97543
0.28325
0.40833
-1.33331
-0.00335
0.15261
0.63733
-2.95310
8.90489
-0.12008
4.76101
0.45178
0.07093
-0.01629
-0.16683
-0.41529
7.71630

2
-18.37015
-4.61120
-2.12144
15.45462
0.30277
0.52933
-1.48136
-0.00666
0.41165
0.15853
-3.29598
9.90209
-0.76278
5.72661
0.48066
0.03310
-0.00550
-0.16362
-0.46038
8.88920

3
-19.32589
-6.59951
-4.18905
11.86630
0.25625
0.45258
-1.64508
-0.00268
0.66741
0.97239
-3.87782
8.45773
0.24382
5.36584
0.99883
0.03998
-0.01071
-0.14494
-0.43821
7.00886

4
-17.29712
-3.16926
-0.71481
16.89943
0.31279
0.47080
-1.54991
-0.00131
0.80092
0.31534
-3.99140
10.58712
0.33302
6.46767
1.01678
0.05901
-0.02100
-0.18290
-0.42611
8.95262

Model
5
-12.51050
-0.28828
1.94791
17.21479
0.25518
0.40157
-1.23218
0.00032
0.47603
0.91250
-3.23291
9.41208
0.91756
5.00653
-0.28447
0.08771
-0.01207
-0.16480
-0.38693
7.20870

6
-15.49182
-2.79137
-0.43564
16.01301
0.26417
0.46022
-1.50129
-0.00118
0.68993
0.93713
-3.84055
9.01481
0.56043
5.41895
0.80912
0.07427
-0.01170
-0.13570
-0.40085
7.37108

7
-16.36435
-4.07530
-1.65859
14.77046
0.23802
0.49360
-1.65449
-0.00244
0.86358
1.21346
-3.96673
7.50451
0.08025
5.08342
1.79139
0.07085
0.00751
-0.09584
-0.38272
6.52085

8
-15.64600
-3.19572
-0.87314
15.44650
0.26055
0.42258
-1.57496
-0.00050
0.67598
1.20583
-3.86795
8.30791
0.54829
5.14513
1.16601
0.07733
-0.00213
-0.12102
-0.41366
6.92264

9
-17.43491
-4.46790
-2.06066
15.72848
0.26173
0.57920
-1.67238
-0.00399
0.29652
1.27797
-3.13702
7.32435
0.15501
4.53131
1.60342
0.04841
0.00578
-0.09770
-0.43272
7.57590

10
-19.22875
-4.14137
-1.57264
17.90211
0.38156
0.63911
-1.74574
-0.00485
-0.33768
0.10076
-3.26825
10.16687
-0.69353
5.79405
-0.09464
0.04390
-0.00212
-0.16108
-0.45423
9.86865

7. 2 Acronyms

BMI – body mass index
BMU – best matching unit
CAD – coronary artery disease
COPD – chronic obstructive pulmonary disease
COVID-19 – coronavirus disease of 2019
CRP – C-reactive protein
DM – diabetes mellitus
ECG - electrocardiogram
FCS – flow cytometry standard
Hgb - hemoglobin
ICC – intraclass correlation
ICP – inductively coupled plasma (membrane)
LDH – lactate dehydrogenase
MAR – missing at random
MCA – multiple correspondence analysis
MCAR – missing completely at random
MICE – multivariate imputation by chained equations
MNAR – missing not at random
OSA – obstructive sleep apnea
PCA – principal component analysis
PMM – predictive mean matching
SOM – self-organizing map
TOF – time of flight
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